** Shares of drug developer Adial Pharmaceuticals rise 12% to $1.11 premarket
** Co says AD04, its lead drug candidate being developed to treat alcohol-use disorder in heavy-drinking patients, showed safety and tolerability consistent with an existing treatment
** Study enrolled 30 healthy adult volunteers, ADIL says
** Says completion of the study satisfied an FDA requirement for the upcoming late-stage trials of the oral drug
** Co plans to meet with FDA in Q4 2024 with the results of the study
** Up to last close, stock down ~47% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments